-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Belite Bio, Raises Price Target to $215

Benzinga·11/13/2026 20:24:07
Listen to the news
Leerink Partners analyst Marc Goodman maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $185 to $215.